Stockreport

BIMZELX® 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count [Yahoo! Finance]

UCB SA UNSP/ADR  (UCBJY) 
NASDAQ:AMEX Investor Relations: ucb.com/investors
PDF At Week 16, patients treated with BIMZELX demonstrated greater draining tunnel reductions versus placebo that were sustained or improved to Week 48 Disease-associated [Read more]